Inventor · disambiguated record
Anita Gandhi
Also filed as: GANDHI ANITA
12 granted patents·21 pending applications·75 citations·filing 2012–2023
89Inventor score
Top patents by PatentIndex Score
33 records- 0196US10047151B2Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictorCELGENE CORP·Filed 2016·Granted Aug 14, 2018·19 cites·5 claims
- 0291US8906932B2Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4Hquinazolin-3-yl)-piperidine-2,6-dioneMULLER GEORGE W·Filed 2012·Granted Dec 9, 2014·15 cites·27 claims
- 0390US9365640B2Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictorLOPEZ-GIRONA ANTONIA·Filed 2012·Granted Jun 14, 2016·16 cites·19 claims
- 0489US10996215B2Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2018·Granted May 4, 2021·5 cites·21 claims
- 0589US9587281B2Cereblon isoforms and their use as biomarkers for therapeutic treatmentCELGENE CORP·Filed 2015·Granted Mar 7, 2017·8 cites·31 claims
- 0683US10689708B2Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugsCELGENE CORP·Filed 2016·Granted Jun 23, 2020·3 cites·11 claims
- 0781US9694015B2Methods for the treatment of locally advanced breast cancerCELGENE CORP·Filed 2013·Granted Jul 4, 2017·5 cites·17 claims
- 0875US10973822B2Combination therapy for treatment of hematological cancers and solid tumorsCELGENE CORP·Filed 2016·Granted Apr 13, 2021·3 cites·69 claims
- 0972US2023159490A1Treatment of immune-related and inflammatory diseasesCELGENE CORP·Filed 2022·Application pending·0 cites
- 1067US11524950B2Treatment of immune-related and inflammatory diseasesCELGENE CORP·Filed 2020·Granted Dec 13, 2022·0 cites·20 claims
- 1167US2022003749A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2021·Application pending·0 cites
- 1265US10919883B2Treatment of immune-related and inflammatory diseasesCELGENE CORP·Filed 2013·Granted Feb 16, 2021·0 cites·12 claims
- 1364US2015038511A1Treatment of immune-related and inflammatory diseasesCELGENE CORP·Filed 2014·Application pending·0 cites
- 1463US2015126538A1Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2014·Application pending·0 cites
- 1563US2019388429A1Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2019·Application pending·0 cites
- 1662US2021340132A1Treatment of immune-related and inflammatory diseasesCELGENE CORP·Filed 2020·Application pending·0 cites
- 1761US2025188545A1Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphomaCELGENE CORP·Filed 2023·Application pending·0 cites
- 1860US9272035B2Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseasesSCHAFER PETER H·Filed 2012·Granted Mar 1, 2016·1 cites·10 claims
- 1959US2018055844A1Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2017·Application pending·0 cites
- 2059US2014045843A1Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2013·Application pending·0 cites
- 2159US2017165266A1Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseasesCELGENE CORP·Filed 2017·Application pending·0 cites
- 2256US2016136167A1Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseasesCELGENE CORP·Filed 2016·Application pending·0 cites
- 2354US2016256468A1Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2016·Application pending·0 cites
- 2454US2016313300A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2014·Application pending·0 cites
- 2552US2017362660A1Cereblon isoforms and their use as biomarkers for therapeutic treatmentCELGENE CORP·Filed 2017·Application pending·0 cites
- 2652US2021102257A1Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor to responsiveness to drugsCELGENE CORP·Filed 2020·Application pending·0 cites
- 2745US10159675B2Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2016·Granted Dec 25, 2018·0 cites·22 claims
- 2844US2017242014A1Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2014·Application pending·0 cites
- 2941US2017157103A1Methods of treating diffuse large b-cell lymphoma using 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2016·Application pending·0 cites
- 3036US2018231561A1Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2016·Application pending·0 cites
- 3136US2017038387A1Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2016·Application pending·0 cites
- 3236US2018238886A1Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compoundsCELGENE CORP·Filed 2018·Application pending·0 cites
- 3331US2017128448A1Combination therapy for cancerCELGENE CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Anita Gandhi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →